Christof Zitt

This inventor holds 9 USPTO granted patents and 3 published patent applications and 12 EPO patents. Top assignees: Takeda Gmbh, Nycomed Gmbh. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christof Zitt. Retrieved from https://idiyas.com/inventor/christof-zitt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 10)

Average Co-Inventor Count = 12.6

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

Years Active: 2009-2016

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9340522 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2016-05-17),

2. 9309187 - EP2 receptor agonists (2016-04-12),

3. 9090597 - Pyrazolone derivatives as PDE4 inhibitors (2015-07-28),

4. 9018175 - 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives (2015-04-28),

5. 8865745 - Pyrazolone derivatives as PDE4 inhibitors (2014-10-21),

6. 8609848 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2013-12-17),

7. 8304436 - Pyrazolone derivatives as PDE4 inhibitors (2012-11-06),

8. 7838521 - 3-oxa-10-aza-phenanthrenes (2010-11-23),

9. 7589205 - 3-thia-10-aza-phenanthrene derivatives (2009-09-15),

Title: Christof Zitt: Innovator in Pharmaceutical Chemistry

Introduction

Christof Zitt is a prominent inventor based in Constance, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of nine patents to his name, Zitt has established himself as a key figure in the industry.

Latest Patents

Among his latest patents are innovative compounds such as Pyrazolone-derivatives and their use as PDE-4 inhibitors. These compounds are recognized for their effectiveness in inhibiting the type 4 phosphodiesterase. Additionally, he has developed EP2 receptor agonists, which are novel effective agonists characterized by specific structural formulas.

Career Highlights

Throughout his career, Christof Zitt has worked with notable companies, including Takeda GmbH and Nycomed GmbH. His work in these organizations has allowed him to advance his research and contribute to the development of new pharmaceutical products.

Collaborations

Zitt has collaborated with esteemed colleagues such as Armin Hatzelmann and Degenhard Marx. These partnerships have further enriched his research endeavors and have led to significant advancements in his field.

Conclusion

Christof Zitt's innovative work in pharmaceutical chemistry and his numerous patents highlight his impact on the industry. His contributions continue to pave the way for new therapeutic solutions.

Profile summary based on public USPTO records.